<DOC>
	<DOCNO>NCT02555657</DOCNO>
	<brief_summary>In study , participant metastatic triple negative breast cancer ( mTNBC ) randomly assign receive either single agent pembrolizumab single agent chemotherapy choose treat physician ( TPC ) accordance local regulation guideline , consist either capecitabine , eribulin , gemcitabine , vinorelbine . The primary study hypothesis pembrolizumab extend progression free and/or overall survival compare TPC</brief_summary>
	<brief_title>Study Single Agent Pembrolizumab ( MK-3475 ) Versus Single Agent Chemotherapy Metastatic Triple Negative Breast Cancer ( MK-3475-119/KEYNOTE-119 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<criteria>Centrally confirm mTNBC Newly obtain tumor biopsy metastatic site Central determination program cell death ligand 1 ( PDL1 ) tumor status Received either one two prior systemic treatment metastatic breast cancer Documented disease progression recent therapy Previously treat anthracycline and/or taxane neoadjuvant/adjuvant metastatic set Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate organ function Participation another clinical trial within 4 week Monoclonal antibody ( mAb ) direct antineoplastic treatment within 4 week Chemotherapy , target small molecule therapy , radiation therapy within least 2 week Active autoimmune disease require systemic treatment past 2 year Diagnosed immunodeficiency receive systemic steroid therapy another form immunosuppressive therapy within 7 day Known additional malignancy require treatment progress last 5 year Known active brain metastasis and/or carcinomatous meningitis Prior therapy antiprogrammed cell death ( PD ) 1 , antiPDligand1 ( antiPDL1 ) , antiPDL2 agent agent direct another coinhibitory Tcell receptor ( e.g . cytotoxic Tlymphocyte associate protein 4 [ CTLA4 ] , OX40 , CD137 ) previously participate Merck pembrolizumab ( MK3475 ) clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-LI</keyword>
</DOC>